Checked
Acumen Pharmaceuticals, Inc.
Nasdaq: ABOS · Biological Products, (No Diagnostic Substances) · Newton, MA
- Net income
- -$121.3M
- Total assets
- $122.8M
- Diluted EPS
- -$2.00
Company details
As reported to the SEC
- SEC CIK
- 1576885
- Stock
- Nasdaq: ABOS
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 1210-1220 Washington Street, Suite 210, Newton, MA 02465
- Incorporated in
- Delaware
- Fiscal year end (SEC record)
- December 31
- Filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- Phone
- (617) 344-4190
- Employer ID (EIN)
- 36-4108129
- Last annual report
- 03/26/2026
- Last quarterly report
- 10/26/2026
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Operating income | -$123.8M | -$114M | -$61.14M | -$45.24M | -$19.58M |
| Net income | -$121.3M | -$102.3M | -$52.37M | -$42.86M | -$100.6M |
| Diluted earnings per share | -$2.00 | -$1.71 | -$1.08 | -$1.06 | -$5.02 |
| Research and development | $104.9M | $93.8M | $42.32M | $32.36M | $12.3M |
| Total assets | $122.8M | $239M | $310.1M | $196.6M | $230.3M |
| Total liabilities | $52.4M | $57.18M | $43.15M | $7.81M | $5.15M |
| Shareholders' equity | $70.43M | $181.8M | $267M | $188.8M | $225.2M |
| Cash and cash equivalents | $53.99M | $35.63M | $66.89M | $130.1M | $122.2M |
| Long-term debt | $22.4M | $29.42M | $29.9M | $0 | Not reported |
| Cash from operations | -$115.5M | -$86.22M | -$43.06M | -$35.15M | -$17.96M |
Recent filings
98 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| S-3Shelf registration statement | 10/26/2026 | None |
| 10-QQuarterly report | 10/26/2026 | 09/30/2026 |
| 8-KResults of operations, Regulation FD disclosure | 10/26/2026 | 10/26/2026 |
| 8-KRegulation FD disclosure | 09/16/2026 | 09/16/2026 |
| DRSSEC filing | 08/12/2026 | None |
| S-8Registration of employee stock plan shares | 08/12/2026 | None |
| 10-QQuarterly report | 08/12/2026 | 06/30/2026 |
| 8-KResults of operations, Regulation FD disclosure | 08/12/2026 | 08/12/2026 |
| 8-KRegulation FD disclosure, Other events | 06/16/2026 | 06/12/2026 |
| 8-KShareholder vote results | 06/03/2026 | 06/03/2026 |
| 10-QQuarterly report | 05/12/2026 | 03/31/2026 |
| 8-KResults of operations, Regulation FD disclosure | 05/12/2026 | 05/12/2026 |
| ARSAnnual report to shareholders | 04/23/2026 | 12/31/2025 |
| DEFA14AAdditional proxy materials | 04/23/2026 | None |
| DEF 14AProxy statement | 04/23/2026 | 12/31/2025 |
| SCHEDULE 13GOwnership report (5% holder, passive) | 04/07/2026 | None |
| EFFECTNotice of effectiveness | 04/01/2026 | None |
| 424B3Prospectus | 04/01/2026 | None |
| CORRESPLetter to the SEC staff | 03/30/2026 | None |
| UPLOADLetter from the SEC staff | 03/30/2026 | None |
83 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Acumen Pharmaceuticals, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 26, 2026.
Frequently asked questions
- What is Acumen Pharmaceuticals, Inc.'s CIK number?
- Acumen Pharmaceuticals, Inc.'s SEC Central Index Key (CIK) is 1576885.
- What is Acumen Pharmaceuticals, Inc.'s stock ticker?
- Acumen Pharmaceuticals, Inc. trades as Nasdaq: ABOS.
- When does Acumen Pharmaceuticals, Inc.'s fiscal year end?
- Acumen Pharmaceuticals, Inc.'s fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Acumen Pharmaceuticals, Inc. headquartered?
- Acumen Pharmaceuticals, Inc.'s principal executive office on file with the SEC is in Newton, MA.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026